Hepatitis C News

Liver disease researchers recently published internally validated models that estimated the risk for hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C based on the presence of cirrhosis and sustained virologic response outcome.

Direct-acting antivirals present not only a highly successful therapy for treatment-naive patients with hepatitis C but also a curative option for patients who could not undergo treatment with interferon-based regimens or failed prior treatment courses.

Outcome Health announced a partnership with the American Liver Foundation to launch a nationwide campaign to promote the recently updated hepatitis C screening recommendations and raise awareness of liver disease, according to a press release.

Baseline resistance associated substitutions did not impact sustained virologic response among direct-acting antiviral-experienced patients who underwent hepatitis C therapy with Vosevi for 12 weeks, according to a recently published study.

The World Health Organization has added ravidasvir as a future pangenotypic direct-acting antiviral to the list of recommended therapies in their Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C, according to a press release.

The FDA recently approved safety and efficacy revisions to the Mavyret label based on data from a hepatitis C/HIV-1 collection study and a liver and renal transplant study.

Patients who were negative for hepatitis C virus and received HCV-infected kidneys and antiviral treatment were clear of the disease and experienced good renal function up to a year after transplantation, according to study results recently published in the Annals of Internal Medicine.

The American Association for the Study of Liver Diseases Foundation announced its investment of $4.06 million in research and career development grants awarded to 36 researchers and clinicians, according to a press release.

Patients without hepatitis C who underwent heart transplantation with an HCV-positive organ were likely to develop HCV viremia posttransplant, but had high rates of sustained virologic response following direct-acting antiviral therapy, according to published results of a recent prospective study.

The American Legion, in partnership with AbbVie, announced the launch of its “Take on Hep C” nationwide initiative designed to provide free hepatitis C antibody testing to veterans and their communities, according to a press release.